Vertex Stock Hits All-Time High of $539.99 as Rival Sionna's CF Drug Fails Phase 2a Trial

Vertex Pharmaceuticals shares surged 5.9% to an all-time high of $539.99 on August 10 after Sionna Therapeutics disclosed that its cystic fibrosis drug candidate SION-719 missed the primary endpoint in its Phase 2a proof-of-concept trial, known as PreciSION CF. The trial was evaluating SION-719, a first-in-class NBD1 stabilizer, as an add-on to Vertex's own Trikafta, the current standard of care in CF. Sionna stock collapsed roughly 90-92% to a record low on the news, effectively removing one of the most closely watched threats to Vertex's dominance in the CF market.

BMO Capital reiterated its rating on Vertex following the rival's trial failure, and Wolfe Research raised its price target on the stock, citing enhanced value for Vertex's CF franchise. Vertex is separately advancing its own next-generation CFTR corrector pipeline, including VX-828 and additional 3.0-class candidates.